Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL6326355 | 0.98 | LMNA (0.48) | LMNAMAPTSMN1; SMN2CYP4Z1RAB9A | |
| SCHEMBL11133611 | 0.91 | F11 (0.47) | LMNAMAPTSMN1; SMN2CYP4Z1RAB9A | |
| SCHEMBL27567003 | 0.84 | GAA (0.53) | LMNAMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL68851 | 0.81 | CYP4Z1 (0.62) | LMNAMAPTSMN1; SMN2CYP4Z1RAB9A | |
| SCHEMBL15955709 | 0.80 | KMT2A (0.60) | LMNAMAPTSMN1; SMN2CYP4Z1RAB9A | |
| SCHEMBL2245806 | 0.80 | RAB9A (0.65) | LMNAMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21402770 | 0.80 | F11 (0.40) | RAB9ANPC1HRH2HRH1 | |
| SCHEMBL13084751 | 0.78 | NPC1 (0.49) | LMNAMAPTRAB9ANPC1KMT2A | |
| SCHEMBL6393097 | 0.78 | ALDH1A1 (0.57) | LMNAMAPTSMN1; SMN2CYP4Z1RAB9A | |
| SCHEMBL2170299 | 0.78 | CA12 (0.61) | LMNAMAPTSMN1; SMN2CYP4Z1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101311165-B | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC | 2011-05-18 | — | — | CN | disclosed |
| CN-100522921-C | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101311165-A | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2008-11-26 | — | — | CN | disclosed |
| CN-1807394-A | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1246312-C | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2006-03-22 | — | — | CN | disclosed |
| US-6700012-B2 | FOR THERAPY OF ALLERGIC DISORDERS | AVENTIS PHARMACEUTICALS INC. | 2004-03-02 | — | — | US | disclosed |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| CN-1308611-A | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMA INC (US) | 2001-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | LMNA 4191/4885MAPT 3333/4885SMN1; SMN2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.